Stockscreener 앱 받기
10.73
10.62%
1.03
시장 영업 전:
10.69
-0.04
-0.37%
전일 마감가:
$9.70
열려 있는:
$9.55
하루 거래량:
83,168
Relative Volume:
1.85
시가총액:
$65.36M
수익:
$5.75M
순이익/손실:
$-38.96M
주가수익비율:
-0.8605
EPS:
-12.47
순현금흐름:
$-32.63M
1주 성능:
+13.19%
1개월 성능:
+42.50%
6개월 성능:
+73.34%
1년 성능:
+53.07%
1일 변동 폭
$9.55
$10.79
1주일 범위
$8.87
$10.79
52주 변동 폭
$4.21
$10.79
칼라 파마슈티컬스 Stock (KALA) Company Profile
명칭
Kala Bio Inc
전화
781-996-5252
주소
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
KALA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
10.73 | 65.36M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
칼라 파마슈티컬스 Stock (KALA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-03-30 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2021-08-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-09-14 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-07-23 | 개시 | Northland Capital | Outperform |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2020-05-27 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-09 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-12-17 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-03-14 | 개시 | Jefferies | Buy |
모두보기
칼라 파마슈티컬스 주식(KALA)의 최신 뉴스
Short Interest in KALA BIO, Inc. (NASDAQ:KALA) Rises By 19.1% - MarketBeat
KALA stock soars to 52-week high, reaching $8.81 - MSN
KALA stock soars to 52-week high, reaching $8.81 By Investing.com - Investing.com Australia
ED Attaches ₹79.78 Crore Assets In Sharon Bio-Medicine’s ₹220 Crore Bank Fraud Case - Free Press Journal
Ramesh Lal Kala , IND candidate bio : Assets , Total Income , Liabilities , Criminal Cases and other details. - The Hindu
KALA BIO Announces $10.75 Million Private Placement Agreement - WilmerHale
Kala Bio executive Todd Bazemore sells $15,206 in stock By Investing.com - Investing.com Australia
Kala Bio's head of research sells $18,662 in stock - Investing.com India
Kala Bio CEO Mark Iwicki sells $44,093 in stock - Investing.com India
Kala Bio's chief business officer sells $15,420 in stock By Investing.com - Investing.com South Africa
Kala Bio’s chief business officer sells $15,420 in stock By Investing.com - Investing.com Nigeria
Kala Bio's head of research sells $18,662 in stock By Investing.com - Investing.com South Africa
Kala Bio CFO Mary Reumuth sells $13,016 in company stock By Investing.com - Investing.com Nigeria
Kala Bio CFO Mary Reumuth sells $13,016 in company stock - Investing.com
Kala Bio's chief business officer sells $15,420 in stock - Investing.com
Baker Bros. Advisors LP Increases Stake in Kala Bio Inc - GuruFocus.com
Baker Bros. Advisors buys $2 million in Kala Bio shares By Investing.com - Investing.com Australia
KALA BIO announces $10.75M private placement - MSN
Baker Bros. Advisors buys $2 million in Kala Bio shares - Investing.com
Kala Bio raises $10.75 million in private placement By Investing.com - Investing.com Canada
KALA BIO Announces Private Placement Agreement with Institutional Investors - Defense World
KALA BIO Secures $10.75 Million in Private Placement to Advance Eye Disease Treatments - Tandav Media
Kala Bio raises $10.75 million in private placement - Investing.com India
KALA Bio Secures $10.75 Million for Eye Disease Treatments: What’s Next for the Biopharma Stock? - Tandav Media
KALA BIO Announces $10,750,000 Private Placement - GlobeNewswire
Global Engine Group Holding Limited Acquires 22.5% Stake in Corpotech Holdings Limited, a Hong Kong Data Centre Operator - The Manila Times
KALA BIO Secures $10.75M Investment from Major Funds, Extends Cash Runway for Key Eye Treatment Trial - StockTitan
Exicure joins hands with GPCR Therapeutics for growth in biotech (NASDAQ:XCUR) - Seeking Alpha
RBC Capital Downgrades HOOKIPA Pharma (HOOK) - MSN
KALA BIO (KALA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Zacks Investment Research
PepGen stock down 22% on FDA clinical hold (update) (PEPG:NASDAQ) - Seeking Alpha
Tracking Baker Brothers Portfolio – Q3 2024 Update - Seeking Alpha
Kala Bio (LTS:0JQ2) EV-to-Revenue : (As of Nov. 30, 2024) - GuruFocus.com
KALAKALA BIO, Inc. Latest Stock News & Market Updates - StockTitan
FTC Solar Announces Reverse Stock Split - The Manila Times
KALA BIO to Present at Piper Sandler Healthcare Conference, Showcasing Eye Disease Pipeline | KALA Stock News - StockTitan
KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
2024 Pharmaceutical Executive APEX Award Winners - Pharmaceutical Executive
Kala Pharmaceuticals Announces IND Submission of its MPP-Formulated Loteprednol Etonbonate (LE-MPP) for Post-Cataract Surgery - Marketscreener.com
Kala Pharmaceuticals retains stock target with Buy rating on trial progress - Investing.com India
60 Degrees Pharmaceuticals’ (SXTP) Neutral Rating Reaffirmed at HC Wainwright - Defense World
Walt Disney (NYSE:DIS) Price Target Raised to $130.00 - Defense World
KALA BIO’s (KALA) Buy Rating Reaffirmed at HC Wainwright - Defense World
ADAR1 Capital Management, LLC Increases Stake in Kala Bio Inc - GuruFocus.com
칼라 파마슈티컬스 (KALA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
칼라 파마슈티컬스 주식 (KALA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Brazzell Romulus K | SEE REMARKS |
Jan 06 '25 |
Sale |
7.63 |
2,446 |
18,663 |
92,418 |
| Iwicki Mark T | CHIEF EXECUTIVE OFFICER |
Jan 06 '25 |
Sale |
7.63 |
5,779 |
44,094 |
280,076 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Jan 06 '25 |
Sale |
7.63 |
1,706 |
13,017 |
68,581 |
0.82%
0.53%
자본화:
|
볼륨(24시간):